These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20424627)

  • 1. Anemia: To TREAT or not to TREAT--that is the question.
    Wiecek A
    Nat Rev Nephrol; 2010 May; 6(5):254-5. PubMed ID: 20424627
    [No Abstract]   [Full Text] [Related]  

  • 2. The TREAT study answers a question, not the question.
    Coyne DW
    Am J Kidney Dis; 2008 Sep; 52(3):626-7; author reply 627-8. PubMed ID: 18725019
    [No Abstract]   [Full Text] [Related]  

  • 3. Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial.
    Hayes C; Alam A; Black-Peart J; McFarlane SI
    Curr Diab Rep; 2010 Apr; 10(2):87-9. PubMed ID: 20425565
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetes, anemia and CKD: Why TREAT?
    Singh AK
    Curr Diab Rep; 2010 Aug; 10(4):291-6. PubMed ID: 20544312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The results of the TREAT study: lessons and limitations].
    Del Vecchio L
    G Ital Nefrol; 2010; 27(1):3. PubMed ID: 20191449
    [No Abstract]   [Full Text] [Related]  

  • 6. Erythropoietin in kidney disease and type 2 diabetes.
    Donnelly S
    N Engl J Med; 2011 Jan; 364(4):385; author reply 385-6. PubMed ID: 21268743
    [No Abstract]   [Full Text] [Related]  

  • 7. Erythropoietin in kidney disease and type 2 diabetes.
    Schnuelle P; Benck U; Krämer BK
    N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268746
    [No Abstract]   [Full Text] [Related]  

  • 8. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
    Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
    N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective trials on anemia of chronic disease: the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).
    Rao M; Pereira BJ
    Kidney Int Suppl; 2003 Nov; (87):S12-9. PubMed ID: 14531768
    [No Abstract]   [Full Text] [Related]  

  • 10. Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):129S-132S. PubMed ID: 12222582
    [No Abstract]   [Full Text] [Related]  

  • 11. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin in kidney disease and type 2 diabetes.
    Locatelli F; Del Vecchio L; Casartelli D
    N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268745
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythropoietin in kidney disease and type 2 diabetes.
    Thum T; Kalantar-Zadeh K; Anker SD
    N Engl J Med; 2011 Jan; 364(4):384-5; author reply 385-6. PubMed ID: 21268744
    [No Abstract]   [Full Text] [Related]  

  • 14. No TREATment with darbepoetin dosed to hemoglobin 13 grams per deciliter in type 2 diabetes with pre-dialysis chronic kidney disease--safety warnings for erythropoiesis-stimulating agents.
    Curtiss FR; Fairman KA
    J Manag Care Pharm; 2009; 15(9):759-65. PubMed ID: 19954267
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacological and clinical profiles of long-lasting erythropoiesis-stimulating agent (darbepoetin alfa; NESP].
    Nagano N
    Nihon Yakurigaku Zasshi; 2008 Apr; 131(4):291-9. PubMed ID: 18408341
    [No Abstract]   [Full Text] [Related]  

  • 16. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
    Grabe DW
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Mc Causland FR; Claggett B; Burdmann EA; Chertow GM; Cooper ME; Eckardt KU; Ivanovich P; Levey AS; Lewis EF; McGill JB; McMurray JJV; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
    Am J Kidney Dis; 2019 Mar; 73(3):309-315. PubMed ID: 30578152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trick or TREAT? More condemning evidence against ESAs.
    Zarowitz BJ
    Geriatr Nurs; 2010; 31(1):52-4. PubMed ID: 20159353
    [No Abstract]   [Full Text] [Related]  

  • 20. Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial.
    Mehta KS; Sinha SD; Vamsi B; Reddy B; Naidu NR; Thakur PA; Sreenivasa C; Reddy VPR; Pandey R; Durugkar S
    J Assoc Physicians India; 2019 Jan; 67(1):62-66. PubMed ID: 30935177
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.